Economic evaluation of long term management strategies for erosive oesophagitis

被引:31
作者
Goeree, R
O'Brien, B
Hunt, R
Blackhouse, G
Willan, A
Watson, J
机构
[1] St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON L8N 4A6, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] McMaster Univ, Dept Med, Div Gastroenterol, Hamilton, ON, Canada
关键词
D O I
10.2165/00019053-199916060-00007
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To compare the expected costs and outcomes of alternative strategies for the management of patients with erosive oesophagitis. Design: There were 3 components to the overall analytic approach. First, a decision model was constructed to compare expected costs and outcomes of 6 management strategies. Second, principles of quantitative literature review and meta-analysis were used to determine probabilities of clinical events (i.e. oesophagitis healing and recurrence). Finally, principles of cost-effectiveness analysis were used to compare treatment alternatives in terms of dominance and incremental cost effectiveness. The viewpoint for the study was that of a provincial government payer for healthcare over a 1-year period. Main outcome measures and results: Healing rates were significantly higher for proton pump inhibitors (PPI) [p < 0.001]. Recurrence rates were significantly higher for intermittent therapy (placebo) and lower for regular dose PPI (p < 0.001). Maintenance prokinetic agent (PA) is dominated (i.e. more costly and less effective) and step-down maintenance PPI is dominated through principles of extended dominance. The 'efficient frontier' is represented by: maintenance H-2-receptor antagonist (H(2)RA), intermittent PPI, step-down maintenance H2RA and maintenance PPI. Conclusions: The price of H(2)RA is a key factor influencing whether step-down maintenance PPI forms part of, or is contained within, the 'efficient frontier' of long term management for erosive oesophagitis.
引用
收藏
页码:679 / 697
页数:19
相关论文
共 104 条
[1]   LAPAROSCOPIC NISSEN FUNDOPLICATION IS A SATISFACTORY ALTERNATIVE TO LONG-TERM OMEPRAZOLE THERAPY [J].
ANVARI, M ;
ALLEN, C ;
BORM, A .
BRITISH JOURNAL OF SURGERY, 1995, 82 (07) :938-942
[2]   CISAPRIDE VERSUS PLACEBO IN REFLUX ESOPHAGITIS - A MULTICENTER DOUBLE-BLIND TRIAL [J].
BALDI, F ;
PORRO, GB ;
DOBRILLA, G ;
IASCONE, C ;
LOBELLO, R ;
MARZIO, L ;
SABBATINI, F ;
TITTOBELLO, A ;
VERME, G .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1988, 10 (06) :614-618
[3]  
Baldi F, 1996, GASTROENTEROLOGY, V110, pA55
[4]  
BARDHAN KD, 1995, ALIMENT PHARM THERAP, V9, P145
[5]  
BARDHAN KD, 1995, GASTROENTEROLOGY, V108, pA53, DOI 10.1016/0016-5085(95)22875-6
[6]   OMEPRAZOLE 10-MG OR 20-MG ONCE-DAILY IN THE PREVENTION OF RECURRENCE OF REFLUX ESOPHAGITIS [J].
BATE, CM ;
BOOTH, SN ;
CROWE, JP ;
MOUNTFORD, RA ;
KEELING, PWN ;
HEPWORTHJONES, B ;
TAYLOR, MD ;
RICHARDSON, PDI ;
MCINYRE, PB ;
MCFARLAND, RJ ;
GREEN, JRB ;
THOMPSON, RPH ;
ROSE, JDR ;
BEVAN, G ;
DANESHMEND, TK ;
CALAM, J ;
OGORMAN, T ;
CLARKE, DN ;
SHREEVE, DR ;
SCHILLER, KF ;
KRASNER, N ;
FOSTER, DN ;
SMITH, PM ;
BATESON, MC ;
BERESFORD, E ;
HEWETT, S .
GUT, 1995, 36 (04) :492-498
[7]   COMPARISON OF OMEPRAZOLE AND CIMETIDINE IN REFLUX ESOPHAGITIS - SYMPTOMATIC, ENDOSCOPIC, AND HISTOLOGICAL EVALUATIONS [J].
BATE, CM ;
KEELING, PWN ;
OMORAIN, C ;
WILKINSON, SP ;
FOSTER, DN ;
MOUNTFORD, RA ;
TEMPERLEY, JM ;
HARVEY, RF ;
THOMPSON, DG ;
DAVIS, M ;
FORGACS, IC ;
BASSETT, KS ;
RICHARDSON, PDI .
GUT, 1990, 31 (09) :968-972
[8]   CANADIAN CONSENSUS CONFERENCE ON THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BECK, IT ;
CONNON, J ;
LEMIRE, S ;
THOMSON, ABR ;
BOURDAGES, R ;
CARMICHAEL, C ;
CHARLAND, N ;
CHAUN, H ;
CLERMONT, R ;
DACOSTA, LR ;
DALY, D ;
DAUPHINEE, WD ;
DEPEW, W ;
DIAMANT, N ;
HADDAD, H ;
HUNT, R ;
JOHNSON, A ;
KLEIN, AV ;
KEITH, R ;
LAY, T ;
LEDDIN, D ;
MACNAUGHTON, D ;
MCHATTIE, J ;
MEDDINGS, JB ;
MERCER, D ;
PATEL, D ;
PATERSON, W ;
PROKIPCHUK, E ;
PROKOPIW, I ;
REYNOLDS, R ;
RIDDELL, RH ;
SHERBANIUK, R ;
SIDOROV, J ;
SHAFFER, EA ;
THOMPSON, WG ;
WILLIAMS, N ;
WOROBETZ, L ;
WRIGHT, J .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 1992, 6 (05) :277-285
[9]  
Biggerstaff BJ, 1997, STAT MED, V16, P753, DOI 10.1002/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO
[10]  
2-G